Ajanta Pharma Limited (NSE:AJANTPHARM)
India · Delayed Price · Currency is INR 3,327.00
+7.40 (0.22%)
Nov 12, 2026, 3:29 PM IST
Ajanta Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 415,661 | 350,323 | 327,581 | 280,899 | 154,878 | 154,667 | |
Market Cap Growth | 29.12% | 6.94% | 16.62% | 81.37% | 0.14% | -0.25% |
Enterprise Value | 410,402 | 343,381 | 320,489 | 276,473 | 149,016 | 149,244 |
Last Close Price | 3324.00 | 2779.64 | 2570.36 | 2166.41 | 1143.51 | 1135.59 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 32.93 | 33.17 | 35.59 | 34.42 | 26.34 | 21.70 |
Forward PE | 30.20 | 29.29 | 31.53 | 31.03 | 20.52 | 19.55 |
PS Ratio | 6.69 | 6.43 | 7.05 | 6.67 | 4.14 | 4.63 |
PB Ratio | 8.56 | 7.74 | 8.64 | 7.87 | 4.57 | 4.74 |
P/TBV Ratio | 8.64 | 7.81 | 8.75 | 7.91 | 4.58 | 4.75 |
P/FCF Ratio | 76.40 | 213.57 | 39.03 | 44.40 | 25.08 | 37.46 |
P/OCF Ratio | 41.78 | 66.20 | 28.31 | 35.78 | 19.55 | 27.54 |
PEG Ratio | 1.68 | 1.79 | 1.58 | 1.55 | 2.89 | 1.49 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 6.60 | 6.30 | 6.90 | 6.57 | 3.98 | 4.47 |
EV/EBITDA Ratio | 23.51 | 23.17 | 25.54 | 23.76 | 18.74 | 16.27 |
EV/EBIT Ratio | 26.14 | 25.88 | 28.40 | 26.44 | 21.92 | 18.47 |
EV/FCF Ratio | 75.43 | 209.34 | 38.19 | 43.70 | 24.13 | 36.15 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.03 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.09 | 0.18 | 0.04 | 0.03 | 0.05 | 0.04 |
Debt / FCF Ratio | 0.28 | 1.62 | 0.06 | 0.06 | 0.06 | 0.08 |
Net Debt / Equity Ratio | -0.11 | -0.09 | -0.15 | -0.12 | -0.24 | -0.09 |
Net Debt / EBITDA Ratio | -0.30 | -0.27 | -0.45 | -0.36 | -1.01 | -0.32 |
Net Debt / FCF Ratio | -0.97 | -2.42 | -0.67 | -0.67 | -1.30 | -0.71 |
Asset Turnover | 1.03 | 0.98 | 0.96 | 0.90 | 0.86 | 0.85 |
Inventory Turnover | 1.56 | 1.37 | 1.32 | 1.36 | 1.38 | 1.14 |
Quick Ratio | 1.90 | 1.88 | 1.85 | 1.98 | 1.71 | 2.15 |
Current Ratio | 2.85 | 2.64 | 2.85 | 3.05 | 2.49 | 3.50 |
Return on Equity (ROE) | 27.53% | 25.39% | 25.02% | 23.47% | 17.68% | 22.77% |
Return on Assets (ROA) | 16.23% | 14.85% | 14.61% | 14.03% | 9.73% | 12.89% |
Return on Invested Capital (ROIC) | 27.77% | 27.64% | 27.41% | 26.73% | 19.30% | 22.50% |
Return on Capital Employed (ROCE) | 30.90% | 28.00% | 28.10% | 27.90% | 19.20% | 23.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.04% | 3.01% | 2.81% | 2.91% | 3.80% | 4.61% |
FCF Yield | 1.31% | 0.47% | 2.56% | 2.25% | 3.99% | 2.67% |
Dividend Yield | 0.84% | 1.00% | 1.07% | 1.62% | 0.57% | 0.53% |
Payout Ratio | 59.34% | 33.12% | 37.96% | 78.68% | 15.25% | 11.54% |
Buyback Yield / Dilution | -0.05% | 0.18% | 0.66% | 1.65% | 1.19% | 0.74% |
Total Shareholder Return | 0.79% | 1.18% | 1.73% | 3.28% | 1.76% | 1.26% |